Elevai Labs, Inc. Common Stock
PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of cutting-edge aesthetic medicines and therapeutic products. The company's lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. It is also involved in the med… Read more
Elevai Labs, Inc. Common Stock (ELAB) - Total Assets
Latest total assets as of September 2025: $14.94 Million USD
Based on the latest financial reports, Elevai Labs, Inc. Common Stock (ELAB) holds total assets worth $14.94 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Elevai Labs, Inc. Common Stock - Total Assets Trend (2020–2024)
This chart illustrates how Elevai Labs, Inc. Common Stock’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Elevai Labs, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2024)
Elevai Labs, Inc. Common Stock's total assets of $14.94 Million consist of 67.3% current assets and 32.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 44.3% |
| Accounts Receivable | $5.28K | 0.1% |
| Inventory | $1.04K | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $2.80 Million | 31.2% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how Elevai Labs, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Elevai Labs, Inc. Common Stock's current assets represent 67.3% of total assets in 2024, a decrease from 100.0% in 2020.
- Cash Position: Cash and equivalents constituted 44.3% of total assets in 2024, down from 78.4% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 31.0% of total assets, an increase from 0.0% in 2020.
- Asset Diversification: The largest asset category is intangible assets at 31.2% of total assets.
Elevai Labs, Inc. Common Stock Competitors by Total Assets
Key competitors of Elevai Labs, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Elevai Labs, Inc. Common Stock - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Elevai Labs, Inc. Common Stock generates 0.27x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Elevai Labs, Inc. Common Stock is currently not profitable relative to its asset base.
Elevai Labs, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.79 | 3.86 | 2.55 |
| Quick Ratio | 1.77 | 3.40 | 2.14 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $4.31 Million | $ 6.10 Million | $ 913.05K |
Elevai Labs, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Elevai Labs, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.26 |
| Latest Market Cap to Assets Ratio | 0.04 |
| Asset Growth Rate (YoY) | 73.3% |
| Total Assets | $8.99 Million |
| Market Capitalization | $387.31K USD |
Valuation Analysis
Below Book Valuation: The market values Elevai Labs, Inc. Common Stock's assets below their book value (0.04 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Elevai Labs, Inc. Common Stock's assets grew by 73.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Elevai Labs, Inc. Common Stock (2020–2024)
The table below shows the annual total assets of Elevai Labs, Inc. Common Stock from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $8.99 Million | +73.28% |
| 2023-12-31 | $5.19 Million | +174.28% |
| 2022-12-31 | $1.89 Million | +184.00% |
| 2021-12-31 | $666.25K | +3814.05% |
| 2020-12-31 | $17.02K | -- |